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CAUSES OF RESISTANT HYPERTENSION IN PATIENTS REFERRED TO A 
TERTIARY CARE CLINIC 
Marko Yakovlevitch, Henry R. Black, Section of Cardiology, 
Department of Internal Medicine, Yale University School of 
Medicine, New Haven, CT 
Current estimates regarding the prevalence, and the 
frequency of causes, of resistant hypertension (HTN) vary 
with clinical setting. We evaluated 301 consecutive 
patients referred to a tertiary care hypertension clinic, 
81 of whom were referred by a physician because of 
resistant HTN. Sixty-one (75%) of those patients met our 
criteria for resistant HTN: failure to achieve blood 
pressure (BP) control with three or more drugs, and 
absence of a known secondary cause at the time of 
referral. 
The cause of resistant HTN was found in 52 patients 
(85%): suboptimal medical regimen in 23, medication 
intolerance in 13, primary noncompliance in 5, secondary 
HTN in 5, psychiatric disorders in 4, white coat HTN in 4, 
alcohol abuse in 1, and a drug interaction in 1. 
BP control was defined as diastolic BP (DBP) < 90mmHg 
and systolic BP < 140mmHg (<_ ISOmmHg for age > 50 and 
< 160mmHg for age > 60). Control was achieved in 30 (55%) 
of those 55 patients who met criteria for resistant HTN 
and returned to clinic at least once, and significant 
improvement (_> 15% fall in DBP) was achieved in another 
six. 
In conclusion, resistant HTN is common in a tertiary 
care setting and is most frequently caused by a suboptimal 
medical regimen; furthermore, the majority of these 
patients can be successfully treated. Of patients who 
were controlled after having been on a suboptimal regimen, 
61% needed initiation of diuretic therapy, and 52% needed 
initiation of therapy with a relatively new agent (calcium 
antagonist or angiotensin-converting enzyme inhibitor). 
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INTRODUCTION 
The prevalence of resistant hypertension, and the 
frequency of the various causes underlying resistance, 
will change as greater information about this condition 
becomes available and as more effective therapy is 
developed. Hypertension that is resistant now may not be 
considered resistant in the future when more powerful and 
better tolerated drugs come into wider use. Even now, 
hypertension that is considered resistant in some settings 
would not be considered resistant in others by virtue of 
varying levels of sophistication from one clinic to 
another. Physicians who have not yet begun to use the 
newest agents, or who neglect the oldest ones, will 
encounter resistance where others would not. 
Despite variability in the classification of 
resistant hypertension, delineating the characteristics of 
patients referred with this diagnosis to a specialty 
clinic will help elucidate the reasons for resistance and 
enable primary physicians to manage this problem more 
successfully. Numerous studies have evaluated potential 
therapies: calcium antagonists1~5 including experimental 
agents such as felodipine,6-9 angiotensin-converting 
enzyme inhibitors,10-15 vasodilators,16-23 doxazosin (also 
an experimental agent), 2 4 - 2 5 furosemide, 2 6 - 2 7 and 
1abetalol28-31 have all shown some effectiveness in the 
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treatment of "resistant hypertension." 
There are very few epidemiological studies of 
resistant hypertension, and it is commonly held that 
resistant hypertension is very unusual.32”34 One study 
which supports this view was reported in 1988; the authors 
sought to determine what proportion of an employed 
hypertensive population have resistant hypertension.32 Of 
1,781 hypertensive patients, only 2.9% were found to be 
resistant, and 63% of those were controlled in subsequent 
years. Since there was some component of noncompliance in 
14 of the 19 patients who remained resistant, the 
investigators concluded that the incidence of resistance 
was 0.3%. However, this population of employees who were 
identified by workplace screening and who elected on-site 
treatment is not representative of the general population 
of hypertensive patients. It should also be noted that 
diagnosing a cause of resistance, such as noncompliance, 
does not necessarily ensure ability to control blood 
pressure. For this reason, I would still categorize 
noncompliant patients with uncontrolled hypertension as 
resistant to therapy. A noncompliant patient requires 
education, a simplified regimen, and possibly other 
therapeutic interventions before blood pressure becomes 
controllable; therefore noncompliance is a form of 
patient-derived resistance. 
The goals of the present study are to determine: 
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1) The frequency of resistant hypertension in a tertiary 
care clinic. 
2) The medical regimens employed by the referring 
physician in those patients. 
3) The frequency of causes of resistance, including 
curable secondary causes. 
4) The proportion of patients meeting criteria for 
resistant hypertension who can ultimately be 
controlled, and the intervention required. 
This information will then be used as the basis for a set 
of guidelines for the evaluation of patients with 
resistant hypertension. 
A set of categories for resistant hypertension is 
presented below using a modification of the schema 
proposed by Frohlich.35 
A) Patient-derived resistance 
1) Patient is unable or unwilling to tolerate side 
effects. Excluded from this category are 
disease-related side effects, such as medically 
unacceptable cardiovascular or renal side effects 
which the patient's physician needs to avoid through 
the selection of appropriate drugs. 
2) Noncompliance with the therapeutic regimen. This is 
believed by some investigators to be among the most 
likely dominant causes.32'36 
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3) Psychological causes such as panic attacks in 
patients with anxiety disorders, or subjective 
medication intolerance resulting from the 
misinterpretation of physical and/or psychological 
stimuli as side effects of medication. 
B) Physician-derived resistance 
1) Failure to identify drug interactions, such as those 
that can arise from nonsteroidal anti-inflammatory 
drugs and oral contraceptives.33'35'37 
2) Failure to identify hypertension-promoting drugs or 
behaviors (such as alcohol abuse) and to educate the 
patient to modify such behaviors.37-39 
3) Use of a suboptimal medical regimen. 
a) Use of suboptimal dosages of standard 
medication in the absence of dose-1imiting 
side effects or patient intolerance. This is 
also believed to be among the most likely 
dominant causes.36 
b) Failure to prescribe standard medication or 
inappropriate choice of medication. For 
example, failure to prescribe diuretics in 
patients with volume-dependent hypertension, 
and failure to substitute loop diuretics for 
thiazides in patients with renal 
insufficiency.40 »41 
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4) Failure to identify and treat correctable secondary 
causes of hypertension, such as renal artery 
stenosis, pheochromocytoma, and primary 
aldosteronism. 
C) Disease-derived resistance 
Resistant essential hypertension in a compliant 
patient who fails to be controlled with optimal 
dosages of three concurrently administered 
antihypertensive agents. 
D) Pseudoresistance 
1) White-coat hypertension: normotension outside of 
the clinic setting. 
2) Pseudohypertension: normal intra-arterial blood 
pressures in a patient with sclerotic brachial 
arteries. 
This study was designed to test the hypothesis that 
resistant hypertension is not an uncommon reason for 
referral to a tertiary hypertension clinic, and that a 
large proportion of the patients referred for resistant 
hypertension have been on a suboptimal medical regimen. 
We have defined resistant hypertension as uncontrolled 
blood pressure despite attempted therapy with at least 
three antihypertensive agents in a patient who is 
considered resistant by a referring physician. Criteria 
for blood pressure control are outlined in table 1. 
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Table 1. Criteria for blood pressure control. 
Acre (years) 
<.50 51 - 60 > 60 
Systolic blood pressure <.140 < 150 < 160 
Diastolic blood pressure £ 90 <_ 90 £ 90 
The criteria for blood pressure control are based 
upon a goal blood pressure independent of the blood 
pressure on referral; this contrasts with the definitions 
accepted by some other investigators.32'37 Predicating 
loss of resistance on the achievement of blood pressure 
control, rather than on a proportionate lowering of blood 
pressure, is in keeping with the aims of antihypertensive 
therapy. Even blood pressures that are moderately 
decreased from their initial levels can be unacceptably 
high; patients who have elevated blood pressures should be 
considered resistant to therapy because the goal of 
therapy is to control, not merely to affect, blood 
pressure. 
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PATIENTS AND METHODS 
Enrollment 
The charts were sought of all patients whose initial 
visit to the Yale Hypertension Clinic was made between 
January 1, 1986 and March 30, 1988. In consultation with 
the clinic attending physician, each patient was 
categorized as to the source of the referral, and 
self-referred patients were distinguished from those who 
were referred by a physician. Those patients who were 
physician-referred were further categorized according to 
the reason for their referral. 
The study group was composed of those patients who 
were physician-referred for assistance with the management 
of "resistant hypertension," and who did not have an 
identified secondary cause for resistance at referral. 
The patients from that group who had been tried on at 
least three antihypertensive agents and whose blood 
pressure was not controlled on their initial visit to the 
hypertension clinic (according to the criteria in table 1) 
were studied in detail. 
Evaluation and Follow-up 
Standard initial evaluation for all patients included 
a complete medical history, past medical history, physical 
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examination, and laboratory studies (unless recent 
laboratory data was provided by the referring physician). 
Initial laboratory evaluation in most patients included a 
urinalysis, complete blood count, determination of serum 
potassium, calcium, creatinine, and glucose, and 
measurement of serum cholesterol and triglyceride levels. 
Further laboratory evaluation for secondary causes of 
hypertension was pursued when history, physical 
examination, or routine laboratory evaluation raised the 
clinical suspicion of such. The criteria used for 
initiation of studies for particular secondary causes have 
been described elsewhere.42 
Dosages of antihypertensive medications were 
interpreted according to the dosage guidelines given in 
the 1984 Report of the Joint National Committee on 
Detection, Evaluation, and Treatment of High Blood 
Pressure;43 for newer agents not included in the 1984 
report, the 1988 report38 was used. The only exception to 
this is indapamide, which was not included in either 
report; dosage guidelines for indapamide were taken from 
the 1988 Physician's Desk Reference.44 
All blood pressures reported in this study are an 
average of two readings (one supine and one standing) 
taken on the same visit, unless the patient's position 
during measurement is stated along with the pressure (in 
which case a single reading is being reported). 
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Achievement of blood pressure control was defined as 
controlled blood pressure on two consecutive visits or on 
the final clinic visit without unacceptable or intolerable 
side effects. The only exception to this is demonstration 
of normotension by 24 hour ambulatory monitoring, with 
greater than 85% of blood pressure readings recorded in 
the normotensive range (according to the criteria in 
table 1). In the context of elevated clinic pressures, 
this established the diagnosis of white-coat hypertension. 
Blood pressure was considered "significantly improved" if 
there was at least a 15% fall in diastolic blood pressure 
(the average of two readings on the final visit compared 
with the average of those on the initial visit). 
Patients were followed until systolic blood pressure 
was less than or equal to 140mmHg and diastolic blood 
pressure was less than or equal to 90mmHg, or control was 
documented by ambulatory monitoring. Those patients in 
whom blood pressure control was not achieved were followed 
until their last clinic visit. 
Final Diagnosis 
The criteria for the diagnosis of specific causes of 
resistance are as follows: 
Patient-derived resistance 
Multiple medication intolerance: inability to 
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achieve therapeutic levels of antihypertensive 
drugs without intolerable side effects despite 
multiple attempts with a variety of agents. 
Noncompliance: patient acknowledgement during 
interview in a consistent clinical setting. 
Psychological causes: 
1) Symptoms of panic disorder with episodic 
elevations in blood pressure. 
2) Misinterpretation of psychological and/or 
physical stimuli as side effects of medication, 
resulting in subjective but non-physiological 
medication intolerance. 
Physician-derived resistance 
Alcohol abuse: temporal correlation of blood 
pressure resistance with high alcohol consumption 
(at least 1.5 ounces of ethanol, or two average 
drinks, per day) such that blood pressure came 
under control only with abstinence from alcohol. 
Suboptimal medical regimen: submaximal dosages of 
antihypertensive agents and/or failure to 
prescribe an indicated agent. 
Secondary causes: 
1) Renal artery stenosis: positive angiographic 
findings in the context of abnormal captopril 
renal scintigraphy and a consistent clinical 
setting. 
11 
2) Primary aldosteronism: positive urinary 
aldosterone studies under a scrupulous 
protocol, which has been described elsewhere,44 
in a consistent clinical setting. Surgery is 
pursued when the cause is presumed to be an 
aldosterone producing adenoma, and in those 
cases provides the opportunity for pathological 
confirmation. 
3) Pheochromocytoma: positive urinary 
catecholamine studies, with positive magnetic 
resonance imaging and/or consistent 
pathological findings in a surgical specimen. 
Pseudoresistance 
White-coat hypertension: normotension outside the 
clinic setting confirmed by 24-hour ambulatory 
monitoring, with greater than 85% of blood 
pressure readings in the normotensive range 
(according to the criteria in table 1). 
Statistical Methods 
All means are arithmetic means, and when reported as 
x +. y, the y value is the standard deviation of the 
sample. Means were compared using critical ratio 
calculations (student's t-test). Categorical data was 
analyzed with chi-square calculations when E (expected 
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value) for each cell was > 5; if this condition was not 
met, then Fisher's exact test was used. The requirement 
for statistical significance was set at p < 0.05, and p 
values are reported only when p < 0.10. When p > 0.10, 
the result is reported as "statistically insignificant." 
Ethical Controls 
The protocol for this study (HIC # 4892) was approved 
by the Human Investigation Committee of the Yale 
University School of Medicine. 
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RESULTS 
Demographic Data and Initial Evaluation 
301 new patients were seen at the Yale Hypertension 
Clinic between January 1, 1986 and March 30, 1988. The 
charts of all but one of these patients were recovered and 
reviewed. The sources of, and reasons for, their 
referrals are outlined in figure 1. 
Figure 1. Sources of, and reasons for, referrals. 
301 new patients 
^--*-l chart lost 
300 patients whose charts were reviewed 
^-> 63 self-referred 
^ r' 
237 physician-referred 
's-->16 referred for problems other than hypertension 
221 referred for hypertension 
-► 30 referred for primary therapy of hypertension 
191 referred for assistance with management of hypertension 
v->110 without "resistant hypertension" 
I 
81 referred for assistance with "resistant hypertension" 
7 referred with a known secondary cause 
74 referred without a known secondary cause for resistance 
v-»-13 judged not to be resistant 
k 
61 met criteria for resistant hypertension 
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Of the 74 patients referred for "resistant 
hypertension" without a known secondary cause, six (8%) 
had had a complete work-up for common secondary causes of 
hypertension prior to their referral, 33 patients (45%) 
had had a limited work-up, and 35 (47%) had none. 
Sixty-one patients (82%) met our criteria for resistant 
hypertension, and they comprised the study group. Their 
demographic and baseline clinical data are presented in 
table 2. Neither age, gender, or race, correlated 
significantly with whether or not a patient satisfied our 




Age 58 + 15 29-85 
Female 34 (56%) 
White 51 (88%) 
Black 6 (10%) 
Asian 1 
Smoking history 36 (59%) 
Current smokers 14 (23%) 
Alcohol history* 3 
Current alcohol* 2 
Family Hx. HTN 33 (54%) 
Hx. of HTN (years) 15 + 11 0.2- 50 
Highest SBP by Hx. 205 + 36 138-300 
Highest DBP by Hx. 118 119 70-170 
Supine SBP 181 + 24 130-240 
Supine DBP 103 t 15 60-140 
Standing SBP 178 + 28 122-246 
Standing DBP 106 ♦ 17 60-150 
♦Consumption of at least 1.5 ounces of ethanol 
(two average drinks) per day. 
Abbreviations: Hx. = history, SBP = systolic 
blood pressure (in nig), DBP = diastolic blood 
pressure (in xxnHg), HTN - hypertension. 
The incidence of other medical conditions in these 
patients is reported in table 3. Coronary artery disease 
was established by a history of typical angina and/or 
electrocardiographic, radionuclide, or other objective 
evidence of ischemia. Diabetes mellitus included diet- 
controlled as well as insulin-dependent diabetic patients. 
Seven of the 13 patients with known renal parenchymal 
disease had renal insufficiency at the time of referral. 
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No patient had a history of pheochromocytoma, primary 
aldosteronism, or congestive heart failure. 
Table 3. Comorbid diseases. 
Patients 
History of myocardial infarction 3 
Coronary artery dis. without MI* 6 
Diabetes mellitus 12 
Renal parenchymal disease 13 
Renal failure 0 
Renal artery disease** 1 
History of gout 3 
History of hyperthyroidism 3 
Medically treated anxiety 10 
Ho comorbid disease 23 
One comorbid disease 27 
Two comorbid diseases 9 
Three comorbid diseases 2 
♦Patients with coronary artery disease without 
a history of myocardial infarction. 
**Hemodynamical1y insignificant renal artery 
disease. 
The drugs being used at the time of referral in these 
patients' regimens are enumerated in table 4 ("INITIAL" 
column). The mean number of agents in those regimens was 
2.3 + 1.1. In this and all subsequent tables, labetalol 
has been included in the category "beta-adrenergic 
blockers." These patients also had a history of having 
been tried on 4 + 3 agents (on average) that were 
discontinued because of side effects or ineffectiveness. 
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Table 4. Frequency of medication use and adiustment of medical regimens. 
H = 61 N = 49* 
Agent INITIAL FINAL Added Removed Increased Decreased 
Diuretics 36 36 22 10 5 4 
Thiazides 16 19 12 3 2 1 
Thiazide/Potassium-sparing** 6 8 5 1 - - 
Loop diuretics 10 8 5 3 3 2 
Potassium-sparing 3 1 0 2 - 1 
Indapamide 1 - “ 1 - “ 
Beta-adrenergic blockers 33 22 4 10 4 1 
Central-adrenergic inhibitors 11 3 - 8 - - 
Reserpine - 1 1 - - - 
Alphai-adrenergic blockers 1 “ “ 1 - - 
Vasodilators 5 3 1 - - 1 
ACE inhibitors 34 31 11 6 3 5 
Calcium antagonists 19 30 18 1 5 3 
‘Does not include patients with alcohol abuse or a secondary disease causing resistance. 
“Fixed combination agents. 
Abbreviations: Thiazides = Thiazides and related sulfonamide diuretics, 
Potassium-sparing = Potassium-sparing diuretics, ACE = Angiotensin-converting enzyme. 
Mean cholesterol and triglycerides levels, measured 
in 46 patients, were 226 +. 45mg/dL and 174 +_ 96mg/dL 
respectively. Mean HDL and LDL levels, measured in 19 and 
18 patients respectively, were 42 +_ 13mg/dL and 
152 +. 44mg/dL. 
Follow-up and Outcome 
Of those 61 patients who met criteria for resistant 
hypertension, 55 returned to clinic at least once, and 
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these comprised the group of resistant hypertensive 
patients who were analyzable; they were followed for an 
average of 10.0 _+ 9.3 months. The final diagnoses along 
with the results of treatment in the clinic are summarized 
in figures 2 and 3. Patients were assigned to categories 
of causes of resistance based upon their meeting the 
specific criteria stated under "Final Diagnosis." In some 
cases, patients met the criteria for more than one cause. 
When both of these causes were important contributors to 
resistance, the patient is reported in a combined 
category; when one was a minor contributor to resistance, 
the patient is reported in the major category alone. 
Minor causes are reported in a footnote of figure 2. 
Of those 55 patients who returned to clinic at least 
once, 30 (55%) were controlled, and another 6 had 
significantly improved blood pressure. Of the remaining 
19, diastolic blood pressure was (not significantly) 
decreased in 9. All three patients with renal artery 
stenosis responded to angioplasty or surgery, and both 
patients with primary aldosteronism were treated 
surgically. 
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Figure 2. Diagnoses and results of treatment. 
61 patients with resistant hypertension 













*In addition to the primary problems enumerated above, six patients had a suboptimal medical regimen, 
three patients had a drug interaction, and two patients had noncompliance as significant but minor 
contributors to their resistance. 
**Blood pressure control was documented in all but one of the six patients with secondary causes or alcohol 
abuse; one of the patients with renal artery stenosis was off all medications after angioplasty and had a 
blood pressure of 138/lOOmnHg on her final clinic visit. The three patients without a clearly established 
cause of resistance did not show significant improvement in blood pressure control. 
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Figure 3, Frequency of types of resistance. 
Table 4 also reports agents used in the final regimen 
of those 49 patients without a curable secondary cause or 
alcohol abuse causing refractory blood pressures (that is, 
those 49 patients with essential hypertension) who 
returned to clinic at least once ("FINAL” column). The 
mean number of agents used was 2.6 +_ 1.3. The therapeutic 
interventions according to class of antihypertensive agent 
used are also recorded in table 4. Fifty-seven new agents 
were added and 36 were removed, while 17 of the original 
agents were increased in dose, and 14 were decreased. 
Of the 29 patients who were found to have a 
suboptimal medical regimen as a cause (either major or 
minor) for their resistance, twenty-eight achieved control 
or significant improvement in their blood pressure. In 
those 23 patients who were completely controlled, 32 
agents were added and 14 were removed, while 11 of the 
original agents were increased in dose, and 9 were 
decreased. The specific agents (by class) are reported in 
table 5. 
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Table 5. Correction of suboptimal regimens. 
N = 23 
Agent Added Removed Increased Decreased 
Diuretics 17 3 2 2 
Thiazides 10 1 1 
Thiazide/Potassium-sparing* 3 1 
Loop diuretics 4 1 1 2 
Beta-adrenergic blockers 1 5 3 1 
Central-adrenergic inhibitors - 4 
Reserpine 1 “ 
Vasodilators 1 1 
ACE inhibitors 3 2 2 3 
Calcium antagonists 9 4 2 
*Pixed combination agents. 
Abbreviations: Thiazides = Thiazides and related sulfonamide diuretics, 
Potassium-sparing = Potassium-sparing diuretics, ACE - Angiotensin-converting enzpe. 
Of the 23 patients who were on a suboptimal medical 
regimen and were subsequently controlled, 21 (91%) needed 
the addition of one or more new agents to their regimen. 
Fourteen of these 23 patients (61%) needed initiation of 
diuretic therapy to achieve control, and another three 
patients needed a change in diuretic agent (one from a 
loop diuretic to a thiazide, two from a thiazide to a loop 
diuretic). Sixteen patients (70%) needed initiation or 
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augmentation of therapy with a relatively new agent: a 
calcium antagonist (12) and/or an angiotensin-converting 
enzyme inhibitor (5). Some patients needed an increase in 
the dosage of medication they were already taking. Of 
those 29 patients who were on a suboptimal medical 
regimen, thirteen (45%) were controlled by the addition, 
or augmentation, of diuretic and/or calcium antagonist 
therapy alone. 
Noncompliance (as a major or minor contributor to 
resistance) was present in sixteen patients; it was 
accompanied by medication intolerance in nine. The 
patients who did not have accompanying medication 
intolerance were more likely to show significant 
improvement in blood pressure than those who did 
(0.05 <. p <_ 0.10). In those seven patients who had 
noncompliance without medication intolerance, the three 
whose regimen was increased in frequency did not have 
significant improvement in blood pressure; the four 
patients whose regimen was decreased in frequency or 
unchanged, did have significant improvement (p < 0.05). 
Frequency of a patient's regimen was defined as the 
frequency of the most frequently taken agent on that 
regimen. 
Covariate Analysis 
Final outcome (controlled vs. not controlled, and 
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controlled or significantly improved vs. neither) did not 
correlate with age, gender, race, presence of particular 
comorbid diseases, number of comorbid diseases, tobacco 
use (prior or present), high alcohol consumption (prior or 
present), duration of hypertension, cholesterol, 
triglyceride, HDL, and LDL levels, or highest blood 
pressures by history (systolic or diastolic). There was a 
trend towards higher diastolic blood pressure (by history) 
in those patients who could not be controlled: controlled 
115 + 18mmHg, controlled or significantly improved 
116 +. 19mmHg, no significant improvement 122 +_ 17mmHg; 
however, the difference was not statistically significant. 
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DISCUSSION 
Resistance to therapy is a subjective experience as 
well as an objective phenomenon. Thus, it is not 
surprising that some patients who are referred for 
resistant hypertension will not meet objective criteria 
for such. The criteria used for inclusion in this study 
were designed to identify those patients who can be 
justifiably called resistant by a referring physician. 
The high frequency of resistance found in this clinic 
population (20% of 300 patients) is in marked contrast to 
the recent study of employed hypertensive patients 
identified by workplace screening which found a less than 
3% incidence.32 However, the investigators in that study 
removed from the "resistant” category all patients who 
achieved a 10% fall in diastolic and 15% fall in systolic 
blood pressure even if final blood pressure remained above 
normal. I disagree with this criterion of categorization 
because those patients still have unacceptable blood 
pressures in spite of medical therapy, and are therefore 
resistant to attempts at controlling blood pressure even 
if they aren't resistant to attempts at improving it. It 
has been suggested previously that severe resistant 
hypertension may be present in 5 to 10% of hypertensive 
patients45 and, as this study shows, the frequency varies 
with clinical setting. The frequency of resistance varies 
with both the clinic's population and the clinic's level 
of expertise in treating the condition. 
Of the 61 patients who met criteria for resistant 
hypertension upon referral, 24 still had resistant 
essential hypertension at the conclusion of the study. 
This means that eight percent of patients seen in this 
tertiary care clinic continued to have uncontrolled blood 
pressure (by the criteria in table 1) through their final 
or most recent, clinic visit. Thus, I would say that in 
the population of patients seen in this hypertension 
clinic, 20% had hypertension resistant to community care, 
and eight percent had hypertension resistant to expert 
care. The majority of patients in this latter group had 
medication intolerance or noncompliance causing 
resistance. 
These patients referred for resistant hypertension 
had (on average) a 15 year history of documented disease, 
with an average of four drugs having been tried and 
discontinued in the past because of side effects or 
ineffectiveness. Nonetheless, the most frequent cause of 
resistance in the community setting was a suboptimal 
medical regimen. Almost half the patients referred for 
resistant hypertension were found to have resistance due 
to a suboptimal medical regimen, and three-quarters of 
those patients could subsequently be controlled. In fact 
all but one of those 29 patients who were on a suboptimal 
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regimen achieved at least a 15% fall in diastolic blood 
pressure if not complete control of systolic and diastolic 
pressures. Addition of a diuretic or use of a newer agent 
such as a calcium antagonist, or augmentation of therapy 
with these agents, proved to be the most successful 
therapeutic maneuver in this group. 
Angiotensin-converting enzyme (ACE) inhibitors were also 
added in a few patients. All the interventions used were 
ones generally available to outpatient clinics. 
The need for calcium antagonists in patients referred 
on suboptimal regimens is probably due to less familiarity 
among referring physicians with these agents. ACE 
inhibitors, which are a few years older than calcium 
antagonists, were added less often. Fifty-seven percent 
of patients who met criteria for resistance at referral 
were referred on ACE inhibitors, while calcium antagonists 
were used in only 31%. Treatment in the Hypertension 
Clinic eliminated the difference; ACE inhibitors were used 
in 65% of patients with essential hypertension, and 
calcium antagonists were used in 61%. Use of these agents 
frequently permitted discontinuation of agents that carry 
more side effects, such as central-adrenergic inhibitors 
and beta-adrenergic blockers. 
The high frequency of inadequate diuretic therapy may 
reflect a growing reluctance to use these agents because 
of the criticism they have received with time. Avoiding 
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diuretics in favor of newer agents causes problems in 
patients with volume-dependent hypertension, which is 
particularly common among patients taking peripheral 
alphai-adrenergic blockers, central alpha2 agonists, 
vasodilators, or peripheral sympathetic blockers.46 The 
need to adequately control volume in hypertensive patients 
cannot be overemphasized, for volume overload alone can 
prevent control of otherwise manageable 
hypertension;26'27'41 this phenomenon has been referred to 
as "pseudotolerance"35 or "pseudo-resistance"46. 
Five patients were referred on vasodilator therapy. 
Two of those did not return to clinic, and a third 
returned only once and was lost to follow-up before a 
diagnosis was established. The vasodilator dosage was 
halved in one of the two remaining patients, and it was 
discontinued in the other. Only one patient was started 
on vasodilator therapy in the Hypertension Clinic (in this 
case, with minoxidil). This patient was intolerant of 
other agents when they were prescribed at dosages that 
controlled blood pressure. In summary, only two patients 
were taking minoxidil at the conclusion of the study. 
Minoxidil is an effective but poorly tolerated treatment 
for resistant hypertension16'18'21'47 and, as shown in the 
present study, is rarely needed now that ACE inhibitors 
and calcium antagonists are available. 
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Secondary causes of hypertension, though not common 
in the general population, were certainly not uncommon in 
this referred group. Of patients meeting our criteria for 
resistant hypertension, eight percent had correctable 
secondary causes. However, the seven patients who were 
referred with a known secondary cause were excluded from 
the present study; when these patients are included, the 
incidence of secondary hypertension becomes 15% of 
patients referred to the clinic for "resistant 
hypertension." The Cleveland Clinic has reported an 11% 
incidence of secondary hypertension among 4,939 patients 
referred to the clinic with hypertension (not necessarily 
resistant) over a two year period.48 Other sources have 
reported a 0.5 to 10% incidence of secondary 
hypertension;42 the broad range arises from variability in 
the kind of populations studied. 
The five percent incidence of renal artery stenosis 
is similar to that reported by a study of 3,520 patients 
referred for evaluation for secondary causes of 
hypertension, which found a three percent incidence,49 as 
well as the four percent incidence found in the Cleveland 
Clinic study mentioned above.48 
Pheochromocytoma and primary aldosteronism are 
reported to have an incidence of 0.1 to 0.5%42'48 in a 
hypertensive population. Therefore, finding no patients 
with pheochromocytoma is consistent with what we would 
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expect, but finding two patients (three percent) with 
primary aldosteronism is a little surprising. Although 
the suggestion of a 20% incidence of "normokalemic 
aldosteronism” in patients with ’’essential hypertension” 
made by Conn50 has been rejected as a lack of appreciation 
of the syndrome of low renin essential hypertension,42 
estimates of the incidence of primary aldosteronism may 
suffer from underdetection owing to the difficulty in 
diagnosing this condition. The small size of that group 
in this study, however, limits the generalizabi1ity of the 
findings. 
Medication intolerance secondary to psychological 
causes was distinguished in this study from medication 
intolerance per se. This was done because patients with 
medication intolerance per se had usual side effects from 
their antihypertensive drugs, but of a magnitude and 
frequency that prohibited the use of therapeutic dosages. 
Those patients who were categorized as having intolerance 
secondary to psychological causes consistently ascribed to 
their medications adverse effects which were considered a 
result of unrelated psychological and physical stresses. 
Finding an acceptable regimen in these patients is 
particularly challenging since the intolerance seems 
largely unrelated to the particular agents prescribed. 
The majority of patients whose blood pressure could not be 
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controlled in the Hypertension Clinic had medication 
intolerance and/or noncompliance causing their resistance. 
Noncompliance was surprisingly underrepresented as a 
cause of resistance; current estimates of noncompliance 
have been as high as 50%,51'52 and as low as 4% in 
patients on simplified regimens.53 It may be that those 
patients willing to pursue treatment in a specialty clinic 
are more likely to be compliant. It is also likely that, 
with the growing awareness of this problem, the incidence 
of undetected noncompliance is falling. Slightly more 
than half of those patients with noncompliance also had 
medication intolerance. Education alone may be of limited 
value in these patients since their noncompliance is 
related to poor tolerance of the agents themselves. These 
patients should be considered separately from those 
without medication intolerance since one is likely to use 
different treatment strategies for the two groups. 
Minimizing dosages and taking the liberty to try a variety 
of agents may be the most useful course of action in the 
patients with medication intolerance and noncompliance, 
while simplification of the medical regimen may be the 
most successful approach in the patients without 
medication intolerance. 
The results in this study show a significant 
correlation between more complex regimens and failure of 
therapy. An earlier study of compliance in elderly 
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hypertensive patients also found that compliance improved 
with reduction in the number of tablets taken, and their 
frequency.53 Other research has suggested that failure in 
understanding is the most frequent problem in noncompliant 
patients;54'55 careful counseling is an important part of 
these patients’ management. Compliance was assessed in 
this study by patient interview, which is not as accurate 
as pill counts or pharmacist logs, but is probably still 
quite reliable.56 
White-coat hypertension was identified in four 
patients. They all required antihypertensive therapy to 
achieve ambulatory normotension, thus they had essential 
hypertension without true resistance. I categorize 
white-coat hypertension as pseudoresistance because it is 
not resistance in the hypertension itself, but rather is 
resistance of a physiological anxiety response: what 
Pickering calls, "a pressor response to the physician."57 
Although 24-hour ambulatory monitoring of every patient is 
currently prohibitive, blood pressure measurements at 
home, or in other settings, may provide clues that a 
patient has white-coat hypertension, as might signs of 
unusual variability in blood pressure. 
Three patients remained undiagnosed. Although these 
are potentially disease-resistant cases, they were all 
lost to follow-up after only two or three visits. It is 
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likely that a cause would have been found if they had 
continued to come to the clinic. 
Diastolic blood pressure control has been defined as 
pressure <_ 90mmHg in other studies24'25 besides this one, 
though some authors have used 95mmHg14'23 or 
lOOmmHg. 3 5 - 5 8 _60 In this study, 90mmHg was accepted as a 
ceiling, since this is the level of diastolic control that 
is believed to be associated with decreased morbidity and 
mortality.38 Systolic blood pressure control was adjusted 
for age to accommodate for isolated systolic hypertension 
in the elderly. Rather than use a cut-off of 150mmHg60 or 
160mmHg35 regardless of age, as has been suggested in some 
discussions of resistant hypertension, the definitions 
were chosen to reflect goals that would be systematic and 
yet individualized. 
Using an average of two blood pressure measurements 
when assessing for blood pressure control serves two 
purposes. Firstly, it decreases the variability 
associated with single measurements; it is for this reason 
also that two consecutive visits with controlled blood 
pressure were required to establish loss of resistance. 
Secondly, being an average of supine and standing blood 
pressures, it assures that supine blood pressure is 
controlled within the limits tolerated by standing blood 
pressure. Supine blood pressure control can be difficult 
to achieve because of postural changes, but it should be 
included in the definition of control since target organ 
damage may progress when only supine blood pressure 
remains uncontrolled.61 
The criteria for demonstrating control of 
hypertension included cases of demonstratiion of control 
on only a single visit if that was the patient's final 
visit to the Hypertension Clinic. This condition was 
included because, being a referral clinic, patients were 
often not seen after control was achieved. Accepting a 
final visit blood pressure as evidence for control helped 
eliminate the bias introduced by discounting as 
uncontrolled all those patients who did not return becaus 
their hypertension became controlled. 
The size of the sample in this study limited the 
likelihood of demonstrating associations between factors 
which may be identified on an initial visit and the final 
categories of resistance (or outcome). Factors that may 
be associated with particular categories of resistance 
according to a previous study include gender, blood 
pressure, body mass index, funduscopic changes, serum 
cholesterol, and fasting blood sugar.32 As in this study 
age, race, smoking history, and a history of angina were 
not found to be significantly associated with final 
diagnosis. Other studies have shown particular agents to 
be more effective in certain subpopulations. For example 
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diltiazem seems to be more effective in older and female 
patients.6 2 
I would conclude from the present study that 
resistant hypertension, the reason for referral in 26% of 
physician-referred patients in this tertiary care clinic, 
is not unusual. Excluding drug interactions and 
noncompliance is the first step in managing these 
patients; likewise, white-coat hypertension and 
pseudohypertension should be considered at the outset. 
The large majority of those patients remaining resistant 
are likely to be on suboptimal medical regimens, and can 
be controlled with changes in their regimens. Many 
patients will be volume expanded, and most will require 
the addition or augmentation of appropriate diuretic 
therapy; some will require adjustment of diuretic therapy, 
such as replacing thiazides with loop diuretics in 
patients with renal insufficiency. Although calcium 
antagonists were also important in achieving control, the 
need for this intervention probably reflects the time lag 
between the introduction of new agents and their 
widespread use. Evaluation for secondary causes of 
hypertension will identify curable diseases in some of the 
patients who remain resistant. Those remaining patients 
without a secondary cause will typically be resistant as a 
result of medication intolerance with or without 
noncompliance. These two problems are often interrelated 
and difficult to correct. Simplifying regimens and 
minimizing adverse side effects will provide some degree 
of success with these patients. An algorithm for the 
management of patients with resistant hypertension 
follows; it is an adaptation of a schema presented 
elsewhere by Black.46 
1. Exclude drug interactions and noncompliance. 
2. Be sure the patient doesn't have white-coat 
hypertension or pseudohypertension. 
3. Be sure the patient isn't volume expanded. 
4. Evaluate the patient for secondary causes of 
hypertension. 
5. Simplify the regimen, if possible, and minimize 
adverse side effects. 
Although the patients referred to a tertiary care 
clinic represent a biased population of hypertensive 
patients, the present study offers some suggestions as t 
approaches that may be productive and effective in 
patients with resistant hypertension, and also provides 
another perspective on the frequency of resistant 
hypertension and its subtypes. 
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